29 results about "Sterol ester" patented technology

Provided herein are methods and materials for using organisms (e.g., engineered yeast strain-derived) to generate lipid compositions which can modulate cellular aging, extend lifespan, and / or modulate gut homeostasis in a subject. The lipid compositions contain at least twelve of the lipids selected from a phosphatidylethanolamine (PE); a lysophosphatidylethanolamine (LPE); a diacylglycerol (DG); a monoglyceride (MG); an acyl carnitine (AcCa); a phosphatidic acid (PA); a phosphatidylglycerol (PG); a lysophosphatidylcholine (LPC); a triacylglycerol (TG); a cholesterol ester (ChE); a wax ester (WE); a phosphatidylserine (PS); a phosphatidylcholine (PC); a phosphatidylinositol (PI); a ceramide (Cer); and a lysophosphatidylserine (LPS).

The invention discloses a genetically engineered bacterium and an application of the genetically engineered bacterium in production of farnesene. The genetically engineered bacterium takes saccharomyces cerevisiae as a chassis strain; an exogenous beta-farnesene synthase gene is integrated, an ERG9 gene is knocked out, a promoter of a truncated HMG1 gene is replaced with an ANB1 promoter, an exogenous transhydrogenase gene is integrated and driven by a glucose sensitive promoter, beta-farnesene synthase is mutated and fused with a transmembrane structural domain of ABC transporter protein PDR10, and then a chimeric expression unit is constructed. According to the present invention, the chassis bacteria are modified by at least one of the steps of overexpression of phosphatidylcholine synthetase, knockout of sterol ester synthetase and introduction of exogenous alkyl glycerol monooxygenase, and the obtained engineering bacteria are combined with the optimized fermentation process so as to significantly improve the farnesene synthesis efficiency and the production economy; therefore, the genetically engineered bacterium and the fermentation method provided by the invention have good application prospects.

This film-forming composition for skin contains the following components (A) to (E). A phospholipid (A) A sterol ester (B) A C10-24 higher alcohol (C) Water (D) Water-insoluble fibers (E) having an average fiber diameter of 0.3 μm to 5 μm and an average fiber length of 20 μm to 300 μm In the film-forming composition for skin, the mass ratio (B) / (E) of component (B) to component (E) is 1 to 15. The water-insoluble fibers of component (E) preferably have a variation coefficient value of the fiber length of 40% to 100%.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

The application provides a recombinant cholesteryl esterase, a polynucleotide thereof, a recombinant plasmid, an expression system and application. The application belongs to the technical field of protein engineering, and specifically, the amino acid sequence of the recombinant cholesteryl esterase provided by the application is shown as SEQ ID No. 1, and the nucleotide sequence for encoding the recombinant cholesteryl esterase is shown as SEQ ID No. 2. The sequence of the recombinant cholesteryl esterase provided by the application has a full length of 482 amino acids, is derived from Aspergillus ruber, has the advantage of high thermal stability, and has a thermal stability deviation of less than 10% after thermal storage at 37 DEG C for 11 days and after 30 days of on-board opening, and has a wide application prospect in the field of in-vitro diagnostic reagents.

The invention discloses a red yeast rice powder-phytosterol ester blood fat reducing formula and an embedding technology, and relates to the technical field of health food, the red yeast rice powder-phytosterol ester blood fat reducing formula comprises, by weight, 30-50 parts of red yeast rice powder, 20-40 parts of phytosterol ester, 10-15 parts of fructo-oligosaccharide, and 1-3 parts of a rosemary extract; through the scientifically verified compounding proportion, the competition of the two components in the intestinal absorption stage is avoided, and the bioavailability is improved. Fructo-oligosaccharide is used as prebiotics, so that intestinal health is promoted, and the absorption capacity of intestinal tracts to active ingredients is improved; the rosemary extract has an anti-oxidation effect, can prolong the oxidation induction period of phytosterol ester to 120 hours, can protect monacolin K and phytosterol ester in the red yeast rice powder from being damaged by external factors such as light and heat, and further improves the stability.

The object of this invention is to provide Labyrinthula microorganisms that have high sterol ester production capacity. [Solution] A Labyrinthull microorganism modified to have reduced or lost activity of sterol 24-C-methyltransferase (SMT1) compared to an unmodified strain, wherein the Labyrinthull microorganism is modified to express a modified diacylglycerol acyltransferase 2C (modified DGAT2C) gene, and the modified diacylglycerol acyltransferase 2C (modified DGAT2C) is modified to have a defect in presumed transmembrane regions 1 to 8 of the presumed transmembrane regions 1 to 12 in diacylglycerol acyltransferase 2C (DGAT2C).

A new class of synthetic cyclodextrin dimers is described. Exemplary cyclodextrin dimers are capable of treating atherosclerotic plaques by targeting various forms of cholesterol both intracellularly and extracellularly. Methods of depleting atherosclerotic plaques of cholesterol, cholesterol esters, 7-ketocholesterol, and 7-ketocholesterol esters by treatment with such cyclodextrins are also provided. A sub-class of dimers with high specificity for 7-ketocholesterol is also described.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of a subject suffering from or at an increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for treating a subject suffering from or having an increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

Cholesteryl ester transfer protein inhibitors for use in the treatment or prevention of cardiovascular disease and pharmaceutical compositions containing the same. The present invention relates to cholesteryl ester transfer protein (CETP) inhibitors for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The utility model relates to the technical field of reactors, and discloses a lipase reactor for efficiently preparing sterol ester, which comprises a reaction box, the top of the reaction box is provided with an open slot, both sides of the open slot are provided with fixing columns, adjacent sides of the two fixing columns are provided with sliding chutes, sliding plates are fixedly connected in the two sliding chutes, and the sliding plates are arranged in the open slot. A motor is fixedly connected to the top of the sliding plate, the output end of the motor penetrates through the sliding plate to be fixedly connected with a stirring rod, a gear is fixedly connected to the outer portion of the upper portion of the stirring rod, electric heating plates are arranged in the two sides of the reaction box, and electric push rods are fixedly connected to the front and rear portions of the top of the reaction box; the output end of the electric push rod is fixedly connected with a cleaning assembly. According to the reaction kettle disclosed by the utility model, the fixed column, the sliding groove, the sliding plate, the motor, the gear, the stirring rod and the rack are matched to work, the motor drives the stirring rod to rotate so as to stir a reaction solution, and the stirring rod can move while stirring, so that the stirring effect is better.

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin / kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

The invention provides a blood fat reducing polypeptide as well as a screening method and application thereof, and belongs to the field of polypeptides. The amino acid sequence of the blood fat reducing polypeptide provided by the invention is FFPFF. The blood fat reducing polypeptide provided by the invention can effectively reduce blood fat, has no obvious toxic or side effect, shows good inhibitory activity on steroid esterase and lipase in an in-vitro enzyme activity test, and also can effectively reduce blood fat in an animal in-vivo experiment; and no obvious toxic or side effect is shown in toxicity prediction and animal in-vivo models.

The present application relates to the technical field of health food and soft capsule preparation, in particular to a kind of full sea-buckthorn oil sterol ester soft capsule and low-temperature homogenization preparation method thereof.The content of the soft capsule is composed of sea-buckthorn seed oil 41.7%, phytosterol 33.3% and sea-buckthorn fruit oil 22% by weight percentage, wherein, sea-buckthorn fruit oil completely replaces soybean oil and chemical synthesis suspending agent, as functional excipient and physical stabilizer, when preparing, high-quality sea-buckthorn oil is extracted at 38±0.5 ℃ subcritical low temperature, and the raw and auxiliary materials are mixed at 38±0.5 ℃ constant temperature;then, pill is pressed at 22-24 ℃ environment, and the accurate temperature difference of 14-16 ℃ is used to stimulate micro-phase rearrangement and viscosity improvement of oil liquid.The present application realizes instantaneous physical homogenization and long-term stable non-layering of content under the condition of zero addition of stabilizer, and realizes efficient comprehensive utilization of sea-buckthorn resources.

This invention discloses a dry chemical reagent for total cholesterol detection, comprising a diffusion layer, a spacer layer, and a reagent layer sequentially overlapped. The diffusion layer includes reflective particles, a binder, a surfactant, cholesterol esterase, and cholesterol oxidase. The reagent layer includes a carrier, horseradish peroxidase, an indicator composition, and a buffer solution. The dry chemical detection reagent of this invention employs a coating method, layering a premixed homogeneous slurry onto a support layer. A spacer layer blocks interlayer interference, and phenolic substances replace photosensitizers as chromogens, combined with a specific ratio of substrate and buffer system. The multi-layered, spacer-free, low-interference vertical detection system constructed by this invention significantly improves the repeatability, accuracy, and stability of the detection reagent.

The utility model relates to a separation and purification system of phytosterol ester, which comprises a pre-mixing module, an extraction module, a saponification module, a liquid separation module, an adsorption module, an evaporator and a dryer, the pre-mixing module is used for mixing and heating an extraction liquid A and an extraction liquid B, the extraction liquid A is insoluble in water and can dissolve the phytosterol ester, and the extraction module is used for extracting the phytosterol ester. The pre-mixing module is provided with an extraction liquid B, the extraction liquid B is dissolved in water and can dissolve phytosterol, a crude product to be separated and purified is added into the extraction module, a weak base solution is added into the saponification module, the adsorption module is filled with activated carbon, and the pre-mixing module, the extraction module, the saponification module and the adsorption module are micro-channel continuous flow modules. The device disclosed by the utility model has the beneficial effects that esterification crude products of fatty acid and phytosterol are separated by utilizing a modularized micro-channel continuous flow extraction technology, and the problem that sterol, fatty acid and sterol ester in the crude products coexist and are difficult to separate is solved, so that high-purity phytosterol ester is obtained.

The present invention relates to a method for determining the content of omega-3 polyunsaturated fatty acids in the retina of a subject comprising the determination of the content of at least one cholesteryl ester in a blood sample from said subject, the content of omega-3 polyunsaturated fatty acids in the retina being correlated to the content of said at least one cholesteryl ester, said at least one cholesteryl ester being cholesteryl 5,8,11,14,17-eicosapentaenoate.

The application relates to the field of skin care products and discloses a ceramide liposome for skin care products and a preparation method thereof, the ceramide liposome comprising the following components in parts by weight: 5-10 parts of hydrogenated lecithin, 0.5-2 parts of modified cholesterols, 0.5-2 parts of ceramides, 0.1-2.5 parts of sucrose stearate, 0.1-1 part of polyglyceryl-10 stearate and 15-30 parts of an organic solvent; the modified cholesterols are prepared by grafting glycine cholesterols and carboxymethyl chitosan through chemical reactions, the glycine cholesterols are prepared by taking cholesterols, N-tert-butoxycarbonylglycine and trifluoroacetic acid as raw materials, and the carboxymethyl chitosan is prepared by grafting chloroacetic acid and chitosan; the ceramide liposome with good stability and good skin barrier repair and moisturizing and water-locking effects is prepared by taking the hydrogenated lecithin, the modified cholesterols, the ceramides, the sucrose stearate and the polyglyceryl-10 stearate as raw materials.

The present application relates to a kind of low-density extracellular vesicles and its preparation method and application, the low-density extracellular vesicles is derived from CD4 + Chimeric antigen receptor T (CD4 + CAR-T) cell culture fluid, after obtaining supernatant by ultracentrifugation, again by ultrafiltration cut-off purification is obtained.The present application is first isolated and identified from CD4 + CAR-T cell a new type of low-density extracellular vesicles (LD-EVs), the subtype is missed in traditional EV separation process, and the cognition to EV diversity is widened.The characteristics of LD-EVs are rich in sterol ester (especially cholesterin ester) by lipidomics etc., which is related to its low-density characteristics and potential membrane stability, signal transmission function, provides target for functional research and engineering modification.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The invention discloses bionic skin lipid and a preparation method thereof. The compound vegetable oil composed of the deep sea fish oil, the camellia seed oil and the prinsepia utilis royle oil is selected, and is rich in triacylglycerol, phytosphingosine, squalene, cholesteryl ester, cholesterol, wax ester, phospholipid and other lipids required by skin; candida lipolytica is adopted to ferment the compound vegetable oil, the bionic skin lipid is obtained after fermentation, the content of effective components and the use feeling are obviously improved, and the bionic skin lipid can be used as an active component to be added into a cosmetic matrix. The multi-dimensional effects of maintaining a skin barrier function, preserving moisture, resisting inflammation, regulating micro-ecology and the like are achieved.

The invention belongs to the technical field of natural food additives, and provides a method for extracting high-purity sterol from residual oil containing sterol ester. By optimizing transesterification reaction conditions and combining a specific strong acid catalyst and a gradient crystallization process, the sterol conversion efficiency and the crystal quality are remarkably improved; catalyst regeneration, solvent closed-loop recovery and seed crystal self-supply technologies are creatively adopted, and product purity breakthrough, resource consumption reduction and environment friendliness improvement are synchronously realized. The problems of impurity eutectic, waste liquid pollution and high cost in the traditional process are solved, and an overall solution is provided for efficient and green extraction of sterol.

Asphalt and asphalt binders and methods for preparing such compositions with sterol esters are disclosed herein. The sterol esters improve various rheological properties of asphalt and asphalt binders. Methods of determining changes or improvements in various rheological properties are also disclosed.

This application provides a lipid-lowering peptide, its screening method, and its application, belonging to the peptide field. The lipid-lowering peptide provided in this application includes at least one of 116 peptides with amino acid sequences such as FFPFF, VFFFPF, PFFFF, AFFFPFF, and LFFFPFY. The lipid-lowering peptide provided in this application can effectively reduce blood lipids without significant toxic side effects. In in vitro enzyme activity tests, it shows good inhibitory activity against sterol esterases and lipases; in vivo animal experiments also show effective reduction of blood lipids; and toxicity prediction and in vivo animal models both show no significant toxic side effects.

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin / kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

This invention discloses the preparation and application of a recombinant cholesterol esterase immobilized enzyme preparation. This invention will... Ophiostoma piceae Cholesterol esterase mutant gene ope-D136P Linked to pPICZαA plasmid, via signal peptide replacement and rDNA Gene insertion yielded the pEESB-3 plasmid; the protein disulfide isomerase gene was inserted. pdi The pPIC9K plasmid was ligated to obtain the pEESB-4 plasmid. This plasmid was electroporated into Pichia pastoris GS115, and after resistance selection and methanol-induced expression selection, recombinant Pichia pastoris engineered strains were obtained. Recombinant cholesterol esterase was obtained from this strain after methanol-induced expression. An aminated immobilization vector was prepared using APTES and TEOS as silane precursors. After grafting with 2,4-dihydroxyacetophenone and nickel ion chelation, the recombinant cholesterol esterase was immobilized to obtain an immobilized enzyme preparation. This immobilized enzyme preparation can catalyze the synthesis of stigmasterol ferulic acid ester from stigmasterol in a non-aqueous phase system, with a conversion rate of 33% (based on stigmasterol) or 32% (based on ferulic acid).

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of a subject suffering from or at an increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for treating a subject suffering from or having an increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The invention provides a blood fat reducing polypeptide as well as a screening method and application thereof, and belongs to the field of polypeptides. The amino acid sequence of the blood fat reducing polypeptide provided by the invention is PFFFF. The blood fat reducing polypeptide provided by the invention can effectively reduce blood fat, has no obvious toxic or side effect, shows good inhibitory activity on steroid esterase and lipase in an in-vitro enzyme activity test, and also can effectively reduce blood fat in an animal in-vivo experiment; and no obvious toxic or side effect is shown in toxicity prediction and animal in-vivo models.